Avadel Pharmaceuticals plc (AVDL) Stock Analysis & Investment Frameworks
Avadel Pharmaceuticals plc (AVDL) stock analysis on Invetso. Review Avadel Pharmaceuticals plc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Avadel Pharmaceuticals plc Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: IE
Avadel Pharmaceuticals plc Key Financial Metrics
- Market Cap: $2.12B
- Revenue: $169.12M
- ROE: 10.25%
- ROIC: 7.86%
- Dividend Yield: N/A
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
Avadel Pharmaceuticals plc Investment Frameworks
Invetso analyzes Avadel Pharmaceuticals plc (AVDL) across the following frameworks:
- Avadel Pharmaceuticals plc 10Y Growth Potential
- Avadel Pharmaceuticals plc Scenario Analysis
- Avadel Pharmaceuticals plc Risks & Opportunities
- Avadel Pharmaceuticals plc Economic Moat
- Avadel Pharmaceuticals plc Business Model
- Avadel Pharmaceuticals plc Management
- Avadel Pharmaceuticals plc SWOT Analysis
- Avadel Pharmaceuticals plc Porter's 5 Forces
- Avadel Pharmaceuticals plc PESTLE Analysis
- Avadel Pharmaceuticals plc ESG Analysis